Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies

Article Details

Authors
Manuel Anguita MD, Mariano de la Figuera MD, Alejandro I Pérez Cabeza MD, Carmen Suarez Fernández MD

Article Type
Original Research

DOI
10.7573/dic.212606

Related Articles

Article Page

Abstract

Aims: To analyze the clinical profile and management of patients with nonvalvular atrial fibrillation taking rivaroxaban in routine practice in Spain.

Methods: Clinical data from the observational studies HEROIC (cardiology and hematology; n=1,727), EMIR (cardiology; n=1,493), BRONCE-AP (primary care; n=133), SILVER-AP (primary care; n=457), ALADIN (internal medicine and neurology; n=249), and ESPARTA (internal medicine; n=110) of patients taking rivaroxaban were analyzed. The clinical profile was compared with those of the XANTUS and ROCKET-AF studies.

Results: Overall, mean age was 74.9±9.4 years, CHA2DS2-VASc score was 3.7±1.5, and 43.2% had a HAS-BLED score ≥3. Patients included in the HEROIC and EMIR studies were older and more frequently had a creatinine clearance <50 mL/min and a higher thromboembolic risk than those in the XANTUS study, and patients included in the ALADIN study were older and had more prior cerebrovascular disease, but a lower thromboembolic risk than those in the ROCKET-AF trial. In those studies with available data, medication adherence and satisfaction with rivaroxaban were high.

Conclusion: Bearing in mind differences according to the clinical setting of each study, atrial fibrillation patients taking rivaroxaban in Spain were elderly and had a high thromboembolic risk. Medication adherence and satisfaction with rivaroxaban were high.

Keywords: atrial fibrillation, clinical practice, rivaroxaban, ROCKET-AF, Spain, XANTUS.

Citation: Anguita M, de la Figuera M, Pérez Cabeza AI, Suarez Fernández C. Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies. Drugs in Context 2019; 8: 212606. DOI: 10.7573/dic.212606

Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: MA has received funding for consultancy services and lecturing from Bayer, Daiichi- Sankyo and Pfizer. MDLF has received funding from Bayer Hispania for designing and publishing SILVER and BRONZE studies. APC has no conflict of interest to declare. CSF has received funding for consultancy services and lecturing from Bayer, Daiichi-Sankyo and Pfizer. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at https://www.drugsincontext.com/wp-content/uploads/2019/09/dic.212606-COI.pdf

Acknowledgments: Editorial assistance was provided by Content Ed Net, Madrid, Spain.

Funding declaration: Editorial assistance was funded by Bayer Hispania.

Copyright: Copyright © 2019 Anguita M, de la Figuera M, Pérez Cabeza AI, Suarez Fernández C. https://doi.org/10.7573/dic.212606. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0, which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2019 Anguita M, de la Figuera M, Pérez Cabeza AI, Suarez Fernández C. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/clinical-profile-and-management-of-rivaroxaban-in-patients-with-atrial-fibrillation-in-routine-practice-in-spain:-data-from-six-nationwide-studies/

Correspondence: Manuel Anguita, Hospital Universitario Reina Sofia, Ctra. Av. Menendez Pidal, s/n, 14004, Córdoba, Spain. manuelp.anguita.sspa@juntadeandalucia.es

Provenance: submitted; externally peer reviewed.

Submitted: 18 June 2019; Peer review comments to author: 13 August 2019; Revised manuscript received: 3 September 2019; Accepted: 9 September 2019; Publication date: 9 October 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions inquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF